Production safety cannot "rely on luck"
Release time:
2021-06-22
In the enterprise, some people have a wrong understanding of safety production management. For example, safety management cannot be prevented. Even if it is done well, accidents may still occur. Accidents are inevitable, and no accidents are completely lucky. In fact, any accident can be avoided. "relying on luck" may have temporary safety, but it will never last long.
"rely on luck", easy to make safety production management a mere formality. With the idea of "relying on luck", the work of production safety is easy to be ignored. The safety inspection of the organization is not checked, the hidden dangers of the governance are not managed, the funds invested in the safety are not invested, and the employees of the training are not trained. Just go to work. Work safety is also neglected under the domination of this wrong idea, and it will be careless and careless in the work, and it is not surprising that accidents will eventually occur. Therefore, in the management of production safety must not have the idea of "relying on luck", but to work conscientiously, strictly implement the rules and regulations and operating procedures, master excellent operation skills and work skills, and effectively prevent accidents.
Safe production depends on standardized operation, excellent equipment and technology, and strict management. The cause of the accident is the unsafe behavior of people and the unsafe state of things and the defects of management. As long as the people, equipment technology and management are done well, the accident can be effectively prevented. If we regard "luck" as a life-saving straw, we are paralyzed, careless and careless about the problem of production safety, and do not take active preventive measures and strict management in terms of people, equipment, technology and management, accidents may occur only by the fluke mentality of "luck. Therefore, we must abandon the idea of "relying on luck" to grasp safety, and should take active countermeasures, carry out preventive management, strengthen on-site management, grasp every safety management link, and implement every safety responsibility and safety measures to completely prevent accidents.
The lesson of blood reminds us that accidents can be avoided, but not "by luck. When any accident occurs, there will be many minor accidents or small signs before it occurs. If attention can be paid to it, careful analysis, investigation and rectification can be carried out, it is possible to avoid accidents. For example, Kunshan dust explosion accident, before the accident, there was a small dust burning accident, and the staff also reflected the dust problem to the management. If the management can pay attention to it and take corresponding prevention and rectification measures, the explosion accident may not happen. However, these minor accidents did not attract the attention and attention of the management, resulting in 97 deaths, 163 injuries and direct economic losses of 3.51 .5 billion yuan.
Safe production is a long-term and complicated work that must be persevered. There is no room for sloppiness. The safe levee cannot have "ant nests", let alone "rely on luck". Only by being serious and responsible, putting the work of production safety into practice, and taking various measures to eliminate the hidden dangers of accidents, can the accident be eliminated in the bud; only by being down-to-earth, doing solid work, operating in strict accordance with regulations, and with a serious and responsible attitude, can we do a good job in production safety.
(from China Safety Production Network, by Sun Xiyun)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page